MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is assess the safety and tolerability of MSB0011359C. Study
consists of dose-escalation part and an expansion part in subjects with metastatic or locally
advanced solid tumors, for which no standard effective therapy exists or a standard therapy
has failed.